Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02797951 · ClinicalTrials.gov registry record · Phase 3
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT02797951 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 165 participants.
The verdict
NCT02797951, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).
Interventions
- DRUG Galcanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2016-07-13 |
| Est. Completion | 2021-01-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02797951
The ClinicalTrials.gov registry entry for NCT02797951 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galcanezumab is the first listed.
NCT02797951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02797951 about?
NCT02797951 is a clinical study titled "A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache". The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).
What is the current status of trial NCT02797951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2016-07-13. Estimated completion is 2021-01-21.
What interventions are being tested in trial NCT02797951?
The interventions under investigation include: Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT02797951?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.